Navigation Links
BioMedomics, Inc. Closes $690K Round of Financing

Research Triangle Park, NC (PRWEB) January 14, 2014

BioMedomics, Inc., a Point of Care (POC) diagnostic company focusing on ultra-sensitive POC diagnostic platforms and novel disease specific POC tests, announced today that it has closed on their first round of financing netting a total of $690,000. The investment is from private investors and is the first outside equity capital in the company. This group of private investors has significant successful experience in early investments in diagnostics companies and includes Tom Roberg who was most recently Vice Chairman of the diagnostic company Advanced Liquid Logic.

Approximately $6 million in non-dilutive monies have already been invested in BioMedomics technologies enabling the company to initiate development of a range of ultra-sensitive diagnostic platforms and novel disease specific tests including acetaminophen overdose, sickle cell disease, and alpha-thalassemia, among others. This investment of outside equity capital will allow the company to meet several significant developmental milestones as well as round out its scientific staff.

“We are thrilled to have such strong support and validation of our technologies from these experienced diagnostics investors,” said Dr. Frank Wang, CEO of BioMedomics, “Our prior grant funding has made it possible to establish an excellent group of diagnostic products. This investment will provide us the ability to focus our efforts on the next stage developmental milestones necessary for additional non-dilutive grants or follow-on capital. We are extremely excited about the potential this funding brings to BioMedomics.”

About BioMedomics, Inc. – BioMedomics was founded in 2006 and is located in Research Triangle Park, NC. BioMedomics is developing advanced highly sensitive and quantitative rapid POC diagnostic platforms and novel disease specific diagnostic tests for the $16 billion POC diagnostic market. The company’s goal is to make POC testing widely accessible with the same level of sensitivity and quantitation as complex and expensive central lab tests.

The core competencies of the company are a strong combination of biology, biochemistry, and biomedical engineering expertise that underline its technology and product development. To meet the increasing need for improved sensitivity in POC diagnostics the company is developing its next generation Time Resolved and Nanotube platforms. Both of these platforms have the potential for sensitivity below the one picogram/mL level. The company also has a particular expertise in developing POC tests for Drugs of Abuse/Overdose and hemoglobinopathies. Tests currently under development include acetaminophen overdose, Sickle Cell Disease, Alpha Thalassemia, and Heparin Induced Thrombocytopenia, among others.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Radius Closes $27.65 Million Second Tranche of Previously Announced Financing
2. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
3. OncoSec Closes $7.75 Million Public Offering
4. AyoxxA Biosystems Closes Series A Financing Round
5. Enviva Closes on $120 Million Senior Secured Credit Facility
6. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
7. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
8. Nasseo, Inc. Joins BioInspire™ Medical Technology Incubator, Closes Seed Funding Round
9. Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
10. iBio, Inc. closes $4.2 million public offering and terminates At-the-market offering
11. Westchester Library Closes Due to Bed Bugs, My Cleaning Products Recommends Pesticide-Exempt Bed Bug Spray to Officials and Others Suffering from the Pests
Post Your Comments:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: ... area for financial services, but it also plays a fundamental ...
Breaking Biology News(10 mins):